Language
English
Publication Date
12-1-2024
Journal
Journal of Controlled Release
DOI
10.1016/j.jconrel.2024.10.036
PMID
39427778
PMCID
PMC11884332
PubMedCentral® Posted Date
3-6-2025
PubMedCentral® Full Text Version
Author MSS
Abstract
Endometriosis, defined by the growth of endometrial tissues outside of the uterine cavity, is a global health burden for ∼200 million women. Patients with endometriosis usually present with chronic pain and are often diagnosed with infertility. The pathogenesis of endometriosis is still an open question; however, tissue stemness and immunological and genetic factors have been extensively discussed in the establishment of endometriotic lesions. Current treatments for endometriosis can be categorized into pharmacological management of hormone levels and surgical removal of the lesions. Both approaches have limited efficacy, with recurrences often encountered; thus, there is no complete cure for the disease or its symptoms. We review the current knowledge of the etiology of endometriosis and summarize the advancement of pharmacological management of endometriosis. We also discuss our efforts in applying DNA-encoded chemistry technology (DEC-Tec) to identify bioactive molecules for the treatment of endometriosis, offering new avenues for developing non-hormonal treatment options for those patients who seek spontaneous pregnancies.
Keywords
Endometriosis, Humans, Female, Drug Development, Animals, Endometriosis, Inflammation, DNA-encoded chemical libraries, High throughput screening, Kinases
Published Open-Access
yes
Recommended Citation
Zian Liao, Diana Monsivais, and Martin M Matzuk, "The Long Road of Drug Development for Endometriosis – Pains, Gains, and Hopes" (2024). Faculty and Staff Publications. 5562.
https://digitalcommons.library.tmc.edu/baylor_docs/5562
Included in
Allergy and Immunology Commons, Biological Phenomena, Cell Phenomena, and Immunity Commons, Obstetrics and Gynecology Commons, Pathology Commons